Predictive factors for response and prognostic factors for long-term survival in consecutive, single institution patients with locally advanced and/or metastatic transitional cell carcinoma following cisplatin-based chemotherapy

Acta Oncologica

Volumn 48, Issue 3, 2009, Pages 411-417

  Jessen, Christian ^a   Agerbaek, Mads ^a   Maase, Hans Von Der ^a  

^a AARHUS UNIVERSITY HOSPITAL   (Denmark)

Author keywords

[No Author keywords available]

Indexed keywords

ALKALINE PHOSPHATASE; CARBOPLATIN; CISPLATIN; CREATININE; DOXORUBICIN; GEMCITABINE; HEMOGLOBIN BETA CHAIN; LACTATE DEHYDROGENASE; METHOTREXATE; MITOXANTRONE; VINBLASTINE; ANTINEOPLASTIC AGENT;

ADULT; ADVANCED CANCER; AGED; ARTICLE; BONE METASTASIS; CANCER CHEMOTHERAPY; CANCER PATIENT; CANCER SURVIVAL; CLINICAL LABORATORY; CLINICAL TRIAL; CREATININE BLOOD LEVEL; FEMALE; GLOMERULUS FILTRATION RATE; HISTOPATHOLOGY; HUMAN; INSTITUTIONAL CARE; LIVER METASTASIS; LUNG METASTASIS; MAJOR CLINICAL STUDY; MALE; METASTASIS; MULTIVARIATE ANALYSIS; PARAMETER; PERFORMANCE; PREDICTOR VARIABLE; PRIORITY JOURNAL; RISK FACTOR; STRATIFICATION; SURVIVAL TIME; TRANSITIONAL CELL CARCINOMA; UNIVARIATE ANALYSIS; VISCERA; VISCERAL METASTASIS; BONE TUMOR; LIVER TUMOR; LUNG TUMOR; MIDDLE AGED; MORTALITY; PATHOLOGY; PHASE 2 CLINICAL TRIAL; PHASE 3 CLINICAL TRIAL; PREDICTION AND FORECASTING; SQUAMOUS CELL CARCINOMA; SURVIVAL RATE; TREATMENT OUTCOME; URINARY TRACT CANCER;

ADULT; AGED; ANTINEOPLASTIC AGENTS; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; BONE NEOPLASMS; CARCINOMA, SQUAMOUS CELL; CARCINOMA, TRANSITIONAL CELL; CISPLATIN; CLINICAL TRIALS, PHASE II AS TOPIC; CLINICAL TRIALS, PHASE III AS TOPIC; FEMALE; HUMANS; LIVER NEOPLASMS; LUNG NEOPLASMS; MALE; MIDDLE AGED; PREDICTIVE VALUE OF TESTS; RISK FACTORS; SURVIVAL RATE; TREATMENT OUTCOME; UROLOGIC NEOPLASMS;

EID: 65349192866     PISSN: 0284186X     EISSN: 1651226X     Source Type: Journal    
DOI: 10.1080/02841860802325932     Document Type: Article

References (22)

1. Roth BJ. Chemotherapy for advanced bladder cancer. Semin Oncol 1996;/23:/633-44.
2. von der Maase H. Current and future perspectives in advanced bladder cancer: Is there a new standard? Semin Oncol 2002;/29(1 Suppl 3):/3-14.
3. Lohrer PJ, Einhorn LH, Elson P, et al. A randomized comparison of cisplatin alone or in combination with methotrexate, vinblastine and doxorubicin in patients with metastatic urothelial carcinome: A cooperative group study. J Clin Oncol 1992;/10:/1066-73.
4. Bellmunt J, Guillem V, Paz-Ares L, Gonzalez-Larriba JL, Carles J, Batiste-Alentorn E, et al. Phase I-II study of paclitaxel, cisplatin, and gemcitabine in advanced transitional-cell carcinoma of the urothelium. Spanish Oncology Genitourinary Group. J Clin Oncol 2000;/18:/3247-55.
5. Stadler WM, Annamaria H, von der Maase H, Debasish R, Dogliotti L, Seymour L, et al. Long-term survival in phase II trials of gemcitabie plus cisplatin for advanced trasitional cell cancer. Urol Oncol 2002;/7:/153-7.
6. Bajorin DF, Dodd PM, Mazumdar M, Fazzari M, McCaffrey JA, Scher HI, et al. Long-term survival in metastatic transitional-cell carcinoma and prognostic factors predicting outcome of therapy. J Clin Oncol 1999;/17:/ 3173-81.
7. Bellmunt J, Albanell J, Paz-Ares L, Climent MA, Gonzalez-Larriba JL, Carles J, et al. Pretreatment prognostic factors for survival in patients with advanced urothelial tumors treated in a phase I/II trial with paclitaxel, cisplatin, and gemcitabine. Cancer 2002;/95:/751-7.
8. Loehrer PJ, Sr, Einhorn LH, Elson PJ, Crawford ED, Kuebler P, Tannock I, et al. A randomized comparison of cisplatin alone or in combination with methotrexate, vinblastine, and doxorubicin in patients with metastatic urothelial carcinoma: A cooperative group study. J Clin Oncol 1992;/10:/1066-73.
9. Sengelov L, Kamby C, Geertsen P, Andersen LJ, von der Maase H. Predictive factors of response to cisplatin-based chemotherapy and the relation of response to survival in patients with metastatic urothelial cancer. Cancer Chemother Pharmacol 2000;/46:/357-64.
10. Sengelov L, Kamby C, von der Maase H. Metastatic urothelial cancer: Evaluation of prognostic factors and change in prognosis during the last twenty years. Eur Urol 2001;/39:/634-42.
11. Bergkvist A, Ljungqvist A, Moberger G. Classification of bladder tumours based on the cellular pattern. Preliminary report of a clinical-pathological study of 300 cases with a minimum follow-up of eight years. Acta Chir Scand 1965;/ 130:/371-8.
12. Sobin LH, Fleming ID. TNM classification of malignant tumors. 5th ed. Union Internationale Contre le Cancer and the American Joint Committee on Cancer. Cancer 1997;/80:/ 1803-4.
13. World Health Organization. WHO handbook for reporting results of cancer treatment. 48th ed. Geneva: WHO offset publication; 1979.
14. Kaplan E, Meier P. Nonparametric estimation from incomplete observations. J Am Stat Assoc 1958;/53:/457-81.
15. Sengelov L, Nielsen OS, Kamby C, von der Maase H. Platinum analogue combination chemotherapy: Cisplatin, carboplatin, and methotrexate in patients with metastatic urothelial tract tumors. A phase II trial with evaluation of prognostic factors. Cancer 1995;/76:/1797-803.
16. Andersen LJ, Sengelov L, Kamby C, von der Maase H. Cisplatin, methotrexate and mitoxantrone in patients with metastatic or advanced urothelial cancer. Acta Oncol 1998;/ 37:/110-2. (Pubitemid 28179810)
17. von der Maase H, Andersen L, Crino L, Weinknecht S, Dogliotti L. Weekly gemcitabine and cisplatin combination therapy in patients with transitional cell carcinoma of the urothelium: A phase II clinical trial. Ann Oncol 1999;/10:/ 1461-5.
18. von der Maase H, Hansen SW, Roberts JT, Dogliotti L, Oliver T, Moore MJ, et al. Gemcitabine and cisplatin versus methotrexate, vinblastine, doxorubicin, and cisplatin in advanced or metastatic bladder cancer: Results of a large, randomized, multinational, multicenter, phase III study. J Clin Oncol 2000;/18:/3068-77.
19. von der Maase H, Geertsen PF, Baekke J, Daugaard G, Sengelov L, Pedersen D, et al. Gemcitabin, cisplatin and paclitaxel (GCP) as first-line treatment of locally advanced and metastatic cell carcinoma (TCC) of the urothelium. American Society of Clinical Oncology. Thirty-Ninth Annual Meeting 2003;/22:/410 .
20. Nilsson S, Ragnhammer P, Nygren P, Glimelius B. A systematic overview of chemotherapy effects in Urothelial bladder cancer. Acta Oncol 2001;/40:/371-90. (Pubitemid 32588129)
21. Ragnhammer P, Brorsson B, Nygren P, Glimelius B. A prospective study of the use of chemotherapy in Sweden and and assessment of the use in relation to scientific evidence. Acta Oncol 2001;/40:/391-411.
22. Mead GM, Russell M, Clark P, et al. A randomized trial comparing methotrexate and vinblastine (MV) with cisplatin, methotrexate and vinblastine (CMV) in advanced transitional cell carcinoma: Results and a report on prognostic factors in a medical research council study. Br J Cancer 1998;/78:/1967-75.